It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Cancers and autoimmune diseases commonly co-exist and immune checkpoint inhibitor therapy (ICI) exacerbates autoimmune pathologies. We recently described a lipidic peptide, designated IK14004, that promotes expansion of immunosuppressive T regulatory (Treg) cells and uncouples interleukin-2 from interferon-gamma production while activating CD8+ T cells. Herein, we report IK14004-mediated inhibition of Lewis lung cancer (LLC) growth and re-invigoration of splenocyte-derived exhausted CD4+ T cells. In human immune cells from healthy donors, IK14004 modulates expression of the T cell receptor α/β subunits, induces Type I IFN expression, stimulates natural killer (NK) cells to express NKG2D/NKp44 receptors and enhances K562 cytotoxicity. In both T and NK cells, IK14004 alters the IL-12 receptor β1/β2 chain ratio to favour IL-12p70 binding. Taken together, this novel peptide offers an opportunity to gain further insight into the complexity of ICI immunotherapy so that autoimmune responses may be minimised without promoting tumour evasion from the immune system.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 InterK Peptide Therapeutics Limited, New South Wales, Australia; University of Queensland, Australian Institute for Bioengineering and Nanotechnology and the ARC Training Centre for Innovation in Biomedical Imaging Technologies, Brisbane, Australia (GRID:grid.1003.2) (ISNI:0000 0000 9320 7537)
2 Auspep Pty Limited, Melbourne, Australia (GRID:grid.1003.2)
3 University of Queensland, Centre for Advanced Imaging, Brisbane, Australia (GRID:grid.1003.2) (ISNI:0000 0000 9320 7537); University of Queensland, Australian Institute for Bioengineering and Nanotechnology and the ARC Training Centre for Innovation in Biomedical Imaging Technologies, Brisbane, Australia (GRID:grid.1003.2) (ISNI:0000 0000 9320 7537)
4 University of Melbourne, Department of Oncology,, Peter MacCallum Cancer Centre and Sir Peter MacCallum, Melbourne, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X)
5 InterK Peptide Therapeutics Limited, New South Wales, Australia (GRID:grid.1008.9)
6 Concept Life Sciences, Edinburgh, Scotland (GRID:grid.470306.6) (ISNI:0000 0004 4910 9410)